Lifesci Capital Has Optimistic Outlook of AVDL Q2 Earnings

Avadel Pharmaceuticals plc (NASDAQ:AVDL - Free Report) - Equities research analysts at Lifesci Capital boosted their Q2 2025 earnings per share (EPS) estimates for Avadel Pharmaceuticals in a research note issued to investors on Thursday, June 5th. Lifesci Capital analyst M. Belghiti now anticipates that the company will earn $0.05 per share for the quarter, up from their previous forecast of $0.02. The consensus estimate for Avadel Pharmaceuticals' current full-year earnings is ($0.51) per share. Lifesci Capital also issued estimates for Avadel Pharmaceuticals' Q4 2025 earnings at $0.19 EPS.

Avadel Pharmaceuticals (NASDAQ:AVDL - Get Free Report) last issued its quarterly earnings results on Wednesday, May 7th. The company reported ($0.05) earnings per share for the quarter, beating the consensus estimate of ($0.07) by $0.02. The company had revenue of $52.51 million during the quarter, compared to analysts' expectations of $50.57 million. Avadel Pharmaceuticals had a negative return on equity of 93.34% and a negative net margin of 52.53%. The business's quarterly revenue was up 93.2% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.30) earnings per share.

Several other equities research analysts have also recently commented on the company. Needham & Company LLC reaffirmed a "buy" rating and set a $19.00 target price on shares of Avadel Pharmaceuticals in a research note on Thursday, May 8th. HC Wainwright reiterated a "buy" rating and set a $21.00 price target on shares of Avadel Pharmaceuticals in a research note on Tuesday, March 4th. Finally, Deutsche Bank Aktiengesellschaft assumed coverage on Avadel Pharmaceuticals in a research note on Tuesday, February 11th. They set a "buy" rating and a $12.00 price target for the company. Seven analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has a consensus rating of "Buy" and an average target price of $19.43.

Avadel Pharmaceuticals Stock Up 3.0%

AVDL opened at $9.72 on Monday. Avadel Pharmaceuticals has a twelve month low of $6.38 and a twelve month high of $17.30. The company has a fifty day moving average of $8.52 and a 200-day moving average of $8.87. The stock has a market cap of $940.30 million, a PE ratio of -12.30 and a beta of 1.45.

Hedge Funds Weigh In On Avadel Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in AVDL. Exencial Wealth Advisors LLC purchased a new position in Avadel Pharmaceuticals in the first quarter valued at approximately $82,000. Thoroughbred Financial Services LLC purchased a new stake in Avadel Pharmaceuticals during the 1st quarter worth about $82,000. Hsbc Holdings PLC purchased a new stake in shares of Avadel Pharmaceuticals in the fourth quarter worth about $113,000. Kovack Advisors Inc. purchased a new stake in Avadel Pharmaceuticals in the 1st quarter worth approximately $90,000. Finally, Kazazian Asset Management LLC bought a new position in shares of Avadel Pharmaceuticals in the fourth quarter worth $126,000. 69.19% of the stock is owned by hedge funds and other institutional investors.

About Avadel Pharmaceuticals

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.